LabCorp and Covance Connect Sponsors with Patients Virtually with an Expanded Suite of Decentralized Trial Solutions

BURLINGTON, N.C. --(BUSINESS WIRE)--Dec. 18, 2019-- LabCorp® (NYSE: LH), a leading global life sciences company that is deeply integrated in guiding patient care, today unveiled its latest solution for decentralized clinical trials from Covance to help transform the conduct of hybrid and virtual

Sensitization profiles to peanut allergens across the United States

Decreased GlycA after lifestyle intervention among obese, prediabetic adolescent Latinos